|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,880.00 ARS | -1.97% |
|
-5.17% | +13.26% |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 07-08 | Morgan Stanley Adjusts Price Target Amgen to $333 From $340, Maintains Equalweight Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AMGN Stock
- AMGN Stock
- Consensus Amgen Inc.
- Estimates Revisions
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
